THREDD
1.8.2024 10:01:31 CEST | Business Wire | Press release
Thredd, the rapidly expanding next-generation global payments platform, reports both industry-wide growth in fintech-led digital payments and the renewal of its partnership with Zilch, the world’s first ad-subsidised payments network (ASPN). This positive trajectory, coupled with recent product and market expansion, adds further momentum to Thredd’s leadership in modern payments processing.
“2024 continues to build on the robust foundation we established in 2023. Our clients, both new and old, are driving strong transaction growth, through a combination of market expansion and increasingly innovative financial services solutions,” said Jim McCarthy, Chief Executive Officer at Thredd. “The expansion we have seen is a testament to their resilience and the demand for new payments use cases in both B2C and rapidly growing B2B payments.”
In February, Thredd noted an atypical early-year uptick in debit and prepaid transactions across several business verticals. This growth has continued in BNPL (+56% YTD), corporate spend management (+74%) and B2C Retail (+28%) transactions.
Success Story: A Growing Partnership with Zilch
BNPL shows no signs of slowing. Since January 2022, Thredd’s clients in this space have seen transaction volumes grow by 175%, reflecting the growing importance of instalment payment options at the point of sale. Leading the way is Zilch, with whom Thredd has recently renewed, retaining the business in a hotly contested evaluation against larger US and European-based competitors. Zilch, one of the world’s fastest growing BNPL providers and a true innovator in this space, offers consumers repayment optionality combined with cashback and rewards through a regulated and unique business model where they uniquely combine the world's $1 trillion dollar advertising with personal credit.
The Zilch-Thredd partnership combines payment network connectivity and transaction management expertise that allows Zilch to focus on its key business objectives of driving billions in commerce to retail partners on ASPN while delivering hundreds of millions of savings, discounts and rewards to their growing customer base. The two companies work collaboratively on product and service innovations to improve the experience of over 4 million customers using Zilch.
“Working together with Zilch since their inception, we’ve had the privilege to be a part of their incredible growth,” said Jim McCarthy. “We sincerely appreciate the trust that Zilch has put in Thredd to help them reach more than 10 million monthly payments, and are looking forward to continuing our close working relationship to help Zilch set further growth records. We’ve seen Zilch grow from zero to over 4 million registered users, gain industry-leading utilisation rates where their customers pay on their platform 100 times a year on average and over $3bn in sales using Thredd as a trusted partner”
Philip Belamant, CEO and Co-Founder of Zilch commented: “Thredd has always allowed us to focus on delivering an unparalleled service to our customers. With Jim at the helm as the driving force of their talented team, it gives us confidence that Zilch will continue to have a reliable and secure payments link in the background as we continue in our next phase of rapid growth and roll-out of innovative products for our customers.”
Rakesh Harji, Chief Operating Officer at Zilch, added: “From inception, our partnership with Thredd has been crucial in building the core infrastructure to securely handle over 10 million monthly transactions and maintain a seamless user experience. Thredd have been with us from zero to over 4m customers and we look forward to continued innovation on product and services as we scale the business and expand our offering to our highly active customers who trust Zilch for their increasing daily lifestyle payment needs.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801143571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
